ETA/EUGOGO Guidelines
Publications
Our multicentric network of Joint TECs around Europe published a huge number of papers in scientific journals. Papers on assessment and treatment recommendations, observational studies as well as RCTs –all of them reflecting the scientific power of a multidisciplinary approach.
Horizon scanning from panel discussions at the EUGOGO Global TED Forum 2025 London
Vickie Lee, Mario Salvi, Anja Eckstein, Colin Dayan and Karim Meeran
Read more: Horizon scanning from panel discussions at the EUGOGO Global TED Forum 2025 LondonPresentation of Graves’ orbitopathy within European Group On Graves’ Orbitopathy (EUGOGO) centres from 2012 to 2019 (PREGO III)
Br J Ophthalmology. 2023;epub ahead of print: doi:10.1136/bjo-2022-322442 A Schuh, A Goksun, L Baldeschi, CR Hintschich et al. on behalf of EUGOGO.
Read more: Presentation of Graves’ orbitopathy within European Group On Graves’ Orbitopathy (EUGOGO) centres from 2012 to 2019 (PREGO III)The 2021 European Group on Graves’ orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves’ orbitopathy.
European Journal of Endocrinology. 2021;185(4):G43-G67. doi.org/10.1530/EJE-21-0479 L Bartalena, GJ Kahaly, L Baldeschi, CM Dayan, A Eckstein, C Marcocci, M Marinò, B Vaidya andWM Wiersinga on behalf of EUGOGO.
Read more: The 2021 European Group on Graves’ orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves’ orbitopathy.Asymmetry indicates worse disease in Graves’ Orbitopathy: results from a prospective cross-sectional multicentre study.
J Endocrinol Invest. 2020 Dec;43(12):1717-1722 P Perros, M Zarkovic et al. on behalf of the European Group on Graves’ Orbitopathy (EUGOGO).
Read more: Asymmetry indicates worse disease in Graves’ Orbitopathy: results from a prospective cross-sectional multicentre study.Predictive score for the development or progression of Graves’ orbitopathy in patients with newly diagnosed Graves’ hyperthyroidism.
Eur J Endocrinol. 2018 Jun;178(6):635-643. doi: 10.1530/EJE-18-0039. Epub 2018 Apr 12. PMID: 29650691 W. Wiersinga, M. Zarkovic, L. Bartalena, S. Donati, P. Perros, O. Okosieme, D. Morris, N. Fichter, J. Lareida, G. von Arx, C. Daumerie, M. Buralcu, G. Kahaly, S. Pitz, B. Beleslin, J. Ciric, G. Ayvaz, O. Konuk, F. Törüner, M. Salvi, D. Covelli, N. Curro, L. Hegedüs, T. Brix on behalf of EUGOGO.
Read more: Predictive score for the development or progression of Graves’ orbitopathy in patients with newly diagnosed Graves’ hyperthyroidism.Mycophenolate plus methylprednisolone versus methylprednisolone alone in active, moderate-to-severe Graves’ orbitopathy (MINGO): a randomised, observer-masked, multicentre trial.
Lancet Diabetes Endocrinol. 2018 Apr;6(4):287-298. doi: 10.1016/S2213-8587(18)30020-2. Epub 2018 Jan 31. PubMed PMID: 29396246. Kahaly GJ, Riedl M, König J, Pitz S, Ponto K, Diana T, Kampmann E, Kolbe E, Eckstein A, Moeller LC, Führer D, Salvi M, Curro N, Campi I, Covelli D, Leo M, Marinò M, Menconi F, Marcocci C, Bartalena L, Perros P, Wiersinga WM; European Group on Graves’ Orbitopathy (EUGOGO).
Read more: Mycophenolate plus methylprednisolone versus methylprednisolone alone in active, moderate-to-severe Graves’ orbitopathy (MINGO): a randomised, observer-masked, multicentre trial.